title: A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema.
abstract: OBJECTIVE
  To compare the safety and efficacy of different doses of intravitreal triamcinolone (ivTA) in treating clinically significant diabetic macular oedema (CSMO).
  
  
  METHODS
  63 eyes of 63 patients with CSMO and central foveal thickness (CFT) of > or =250 microm on optical coherence tomography were randomised to receive 4 mg (n = 23), 6 mg (n = 20) or 8 mg (n = 20) ivTA. Patients were followed up for 6 months, and changes in best-corrected visual acuity (BCVA), optical coherence tomography CFT, standardised change in macular thickness (SCMT), and side effects such as intraocular pressure and cataractogenesis were compared between the three groups.
  
  
  RESULTS
  After ivTA injection, improvements of BCVA and CFT occurred in all groups. The mean BCVA improvement at 6 months was significantly higher for the 8 mg group compared with the 4 mg group, with 9.9 and 3.1 improvement in letters on the Early Treatment of Diabetic Retinopathy Study chart, respectively (p = 0.047). The mean SCMT at 6 months for the 4, 6 and 8 mg groups was 28.7%, 42.3% and 60.5%, respectively (p = 0.06). The proportion of eyes with SCMT > or =75% at 6 months was higher in the 8 mg group, but the difference failed to reach significance (p = 0.06). Ocular hypertensive responses (>21 mm Hg) occurred in 39%, 30% and 55% of eyes in the 4, 6, and 8 mg groups, respectively (p = 0.27).
  
  
  CONCLUSIONS
  Higher doses of ivTA may prolong the duration of visual benefit in diabetic CSMO and seemed to result in more sustained reduction in macular oedema. Further studies are warranted to investigate the optimum dose of ivTA in treating diabetic CSMO.
authors.affiliation: Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong. dennislam_pub@cuhk.edu.hk
authors.forename: Dennis S C
authors.initials: DS
authors.lastname: Lam
authors.forename: Carmen K M
authors.initials: CK
authors.lastname: Chan
authors.forename: Shaheeda
authors.initials: S
authors.lastname: Mohamed
authors.forename: Timothy Y Y
authors.initials: TY
authors.lastname: Lai
authors.forename: Kenneth K W
authors.initials: KK
authors.lastname: Li
authors.forename: Patrick S H
authors.initials: PS
authors.lastname: Li
authors.forename: Chi-Wai
authors.initials: CW
authors.lastname: Tsang
authors.forename: Wai-Man
authors.initials: WM
authors.lastname: Chan
authors.forename: Mahesh P
authors.initials: MP
authors.lastname: Shanmugam
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005584:Fovea Centralis / Q000473:pathology; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced; D011446:Prospective Studies; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D014222:Triamcinolone Acetonide